Huxley Medical has filed a notice of an exempt offering of securities to raise $11,700,000.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Huxley Medical is raising up to $11,700,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Huxley Medical
Huxley Medical is a healthcare technology company focused on streamlining the diagnosis of sleep-disordered breathing through its SANSA diagnostic platform. SANSA is a cellular-enabled monitor that assesses obstructive sleep apnea, central sleep apnea, and ECG through a single device, supported by intuitive AI, actionable reporting, and scalable workflows. The platform is designed for use across sleep labs, cardiology clinics, and primary care, with three service modelsSANSA Express, SANSA GO, and SANSA 360intended to simplify testing and expand access to care. Its wire-free, belt-free, probe-free design automatically uploads data without requiring a smartphone, Bluetooth connection, or app. Huxley Medical reports that SANSA was validated against in-lab polysomnography in a large multi-site study, achieving 95% sensitivity for sleep apnea and 99% accuracy for central sleep apnea. The company has also announced FDA clearances for its cellular-enabled home sleep apnea test, central sleep apnea detection, and diagnostic ECG capabilities.

To learn more, visit https://www.huxleymed.com/
LinkedIn: https://www.linkedin.com/company/huxley-medical-inc/

Contact:
Christopher Lee, Chief Executive Officer
https://www.linkedin.com/in/chris-lee-20995922/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.